We previously reported that the measurements of stool decay-accelerating factor (DAF), a membrane-bound, complement regulatory protein, may be valuable for the detection of colorectal cancer. Recently we have refined the immunoassay for stool DAF. In the present study, using the refined assay, we measured stool DAF concentrations in multiple samples from patients with colorectal cancer and in healthy controls to determine whether testing of multiple samples would increase the sensitivity of the stool DAF test.
INTRODUCTION
Colorectal cancer is one of leading causes of cancer mortality in industrialized countries. Fecal occult blood (FOB) testing has been widely used as a screening test for colorectal cancer, but its efficacy is still controversial (1) (2) (3) (4) (5) (6) . More reliable stool markers for the detection of colorectal cancer screening are needed.
Decay-accelerating factor (DAF; CD55) is a membrane-bound glycoprotein that regulates the activation of the autologous complement activation by inhibiting the formation and promoting the catabolism of C3 and C5 convertases (7, 8) . We previously showed enhanced expression of DAF in human GI tracts of various pathological conditions (9 -12) . Expression of DAF was remarkably enhanced on the luminal surface and in the gland lumens of colorectal cancers (9) . Growth factor stimulation may be related to the enhanced expression of DAF through the mitogen-activated protein kinase pathway (13) . We have also measured stool DAF in patients with colorectal cancer and found that their stools contained increased amounts of DAF (14) . Our findings thus far have indicated that measurements of stool DAF may be a valuable test for the detection of colorectal cancer.
Accordingly, we have worked to develop a clinically useful immunoassay for the measurement of stool DAF and have established a reliable ELISA (15, 16) . In the present study, we measured stool DAF concentrations in multiple samples from patients with colorectal cancer and from healthy controls and investigated whether testing of multiple samples would increase the sensitivity of the stool DAF test.
MATERIALS AND METHODS
Three spontaneously passed stool samples (1-5 g) were obtained from each of 100 patients with colorectal cancer (45 women and 55 men; age range, 29 -90 yr; mean age 66 yr) and 100 control subjects who underwent total colonoscopic examination because of abdominal symptoms or screening for colorectal cancer and were found to have no colorectal disease (40 women and 60 men; age range, 17-84 yr; mean age 56 yr). Of the 100 colorectal cancers, 38 were located in the rectum, 22 in the sigmoid colon, seven in the descending colon, 11 in the transverse colon, 16 in the ascending colon, and six in the cecum. The cancers ranged from 8 to 100 mm in diameter. The TNM stage of the colorectal cancers (17) was 0 (n ϭ 8), I (n ϭ 15), II (n ϭ 25), III (n ϭ 39), and IV (n ϭ 13). The stools were weighted and suspended in three times weight of phosphate-buffered saline containing 1% bovine serum albumin, 0.05% Tween 20, and 1 mmol/L phenylmethylsulfonylfluoride with increased NaCl concentration (0.4 mol/L) to reduce nonspecific reactions as described (16) . The suspensions were centrifuged at 8000 g for a few seconds in a bench-top microcentrifuge (15) , and the supernatants were collected and kept frozen at Ϫ80°C until use. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the local Ethics Committee. Informed consent was obtained from each patient.
Details of our methods for the measurement of stool DAF using the new ELISA have been described (15, 16) . Briefly, human DAF was purified from pooled human erythrocyte stroma, and mouse monoclonal antibodies to DAF were prepared (18) . Two of these mouse monoclonal antibodies (IgG1), clones 1C6 and 4F11, were used. The 1C6 antibody is directed to the active site on the DAF molecule, i.e., short consensus repeat (SCR) 3, and the 4F11 antibody recognizes SCR 4 (19) . The 1C6 monoclonal antibody was labeled with horseradish peroxidase (HRP) as described (20) . The wells of microtiter plates were coated with 4F11 monoclonal anti-DAF antibody, and serially diluted stool supernatants were added to the wells. After further washing, HRP-labeled 1C6 anti-DAF antibody was added. After washing, bound 1C6 antibody was detected with 2,2Ј-azino-di-3-ethylbenzo-thiazoline-6-sulfonic acid as substrate. Absorbances at 415 nm were measured on an automated ELISA plate reader. A calibration curve was obtained from several dilutions of known quantities of purified DAF, and the concentrations of stool DAF were calculated. Samples were analyzed in duplicate.
The same stools analyzed for DAF were also tested for FOB with guaiac-impregnated paper slides (Occult Blood Slide Shionogi; Shionogi, Tokyo, Japan) and immunological tests for human Hb in feces (OC-Hemodia-Eiken; Eiken Chemical, Tokyo, Japan) according to the manufacturer's instructions. These FOB tests were performed on fresh stools (Ͻ24 h old).
Stool samples were coded, and the measurement of stool DAF and the FOB test were performed by two investigators (M.M., N. I.) who had no knowledge of the background of stools under examination.
For statistical analysis, the Mann-Whitney U test, McNemar's test, and 2 test were used.
RESULTS
The distribution of stool DAF concentrations in the patient and control group is shown in Figure 1 . Concentrations in the patients with colorectal cancer (median 11.1 ng/g stool; interquartile range 2.9 -32.7 ng/g) were significantly higher than the concentrations in the subjects without colorectal disease (median 1.6 ng/g stool; interquartile range 0.4 -3.4 ng/g) (p Ͻ 0.0001, Mann-Whitney U test). The reference interval for stool DAF was calculated as Յ10.8 ng/g. On the basis of these data, we defined a cut-off value of stool DAF for detection of colorectal cancer by constructing a receiver operating characteristic (ROC) curve (21) (Fig. 2 ) and temporarily chose a cut off value of 9 ng/g stool. This cut-off value corresponded to the point at which the incline of the ROC curve showed a steep change and a high specificity was obtained, which we considered suitable in the screening setting for colorectal cancer. Box plots of stool DAF concentrations in patients with colorectal cancer and in control subjects without apparent colorectal disease. Boxes indicate median and 25th and 75th percentiles; bars indicate 10th and 90th percentiles. Three stool specimens from each patient (n ϭ 100) and normal subject (n ϭ 100) were analyzed. Colorectal cancer vs control, p Ͻ 0.0001 (Mann-Whitney U test).
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We then asked whether testing of multiple stool samples from each patient would increase the sensitivity of the stool DAF test. As shown in Table 1 , the sensitivity was 44.0% for 1-day testing, 72.0% for 2-day testing, and 82.0% for 3-day testing, with the sensitivity being significantly greater for both 2-day and 3-day testing versus 1-day testing (p Ͻ 0.01; McNemar's test). The specificity was 96.0% for 1-day testing, 92.0% for 2-day testing, and 89.0% for 3-day testing; the difference in the specificity between 1-day and 2-day testing was not significant, but the difference between 1-day and 3-day testing was significant (p Ͻ 0.05). Thus, for subsequent analysis of the sensitivity of the stool DAF test in relation to size, location, and TNM stage of colorectal cancers we used 2-day testing.
The sensitivity significantly increased according to the tumor size (p ϭ 0.0001), with the sensitivity being 35% for tumors Յ2 cm in maximal diameter and 88% for tumors Ͼ5 cm in diameter ( Table 2 ). The sensitivity of the test for detecting distal cancer was slightly higher than that for proximal cancer, but the difference did not reach statistical significance (p ϭ 0.07) ( Table 2 ). The sensitivity was independent of TNM stage (p ϭ 0.18) ( Table 2 ). The test was positive in a substantial portion of patients with noninvasive cancer, i.e., four of eight patients (50%) who had TNM stage 0 tumors, in eight of 15 patients (53%) who had TNM stage I tumors, and in 19 of 25 patients (76%) who had TNM stage II tumors (Table 2) .
FOB was detected in 62 and 75 of 100 patients with colorectal cancer by guaiac and immunological tests, respectively, as compared with 72 of the 100 detected by the DAF test. The stool DAF test was positive in 25 of 38 patients (66%) who had a negative guaiac test and 13 of 25 patients (52%) who had a negative immunological test (Table 3). When the stool DAF test was combined with FOB testing, the sensitivity for detection of colorectal cancer significantly increased by 25% in conjunction with the guaiac test (p Ͻ 0.01, 2 test) and by 13% (p Ͻ 0.05) with the immunological test, without statistically significant decrease in specificity (Table 4 ). 
DISCUSSION
In this study, we measured stool DAF concentrations in patients with colorectal cancer and in healthy controls by use of our recently refined ELISA (15, 16) . The major finding was that testing of two samples from each patient significantly increased the sensitivity of the stool DAF test without significantly decreasing its specificity (the sensitivity of the 2-day testing was 72% and the specificity 92%). For screening for colorectal cancer, FOB testing has been widely used, and multiple stool sampling is common. Threeday sampling, with guaiac-impregnated chemical tests, is used often in Western countries (1, 3) , and 2-day sampling, with chosen immunochemical tests, is used often in Japan (22, 23) . In our stool DAF test, we found that 3-day sampling significantly increased the sensitivity when compared with 1-day or 2-day sampling, but with a significant decrease in specificity between 1-day and 3-day testing. Thus, we chose 2-day testing as optimal for combined sensitivity and specificity and used the 2-day testing for further analysis of the stool DAF test in relation to size, location, and TNM stage of colorectal cancers.
One of the limitations of FOB testing is that some colorectal cancers do not cause significant fecal bleeding (24, 25) . We showed previously that stool DAF was sometimes detected without concurrent bleeding in colorectal cancer patients (14) . In this study, we found that the stool DAF was slightly more sensitive for detecting colorectal cancers than was the guaiac test (72% vs 62%) and equal in sensitivity to the immunological test (75%). Importantly, we found that the stool DAF test was positive in more than one half of patients with negative FOB test, and we confirmed that stool DAF could be a marker of colorectal cancer independent of FOB testing. Also, by combining the stool DAF test with FOB testing, the sensitivity for detection of colorectal cancer was significantly increased without an associated decrease in specificity. The combined findings suggest that stool DAF test may be at least useful as an adjunctive tool to FOB testing in stool screening for the detection of colorectal cancer.
Another important limitation of FOB testing is that FOB is not specific to colorectal cancer, which causes high false positive rates and leads to unnecessary colonoscopies, thus increasing screening costs (5, 6) . DNA alterations specific for neoplasm, such as mutations in oncogenes and tumor suppressor genes, are candidate markers to overcome this obstacle, and several investigators have reported that such DNA alterations can be detected in stools of colorectal cancer patients (26 -34) . However, the DNA tests require technically complicated procedures, and whether DNA is consistently stable in stool has not fully been established; appropriate processing of stool specimens may be mandatory. In contrast, stool DAF can be measured in an ordinary immunoassay that can be performed even in small clinical laboratories. Moreover, DAF protein is known to be resistant to digestion by proteolytic enzymes (35) and to be heat stable (36) for at least 24 h after defecation, even when specimens are maintained at room temperature (37) . These advantages allow patients to send stool samples by mail and may facilitate compliance with screening program for colorectal cancer. We emphasize also that our stool DAF ELISA uses a uniform source of antibodies, i.e., two mouse monoclonal antibodies (15, 16) , thus allowing us to supply and apply the DAF assay consistently for routine use.
Because we had previously shown immunohistochemically an increased expression of DAF in colorectal adenoma, although less than in colorectal cancer (9) , detection of stool DAF would be expected in patients with adenomatous polyps. In our previous study in which stool DAF amounts in patients with colorectal adenomas were examined (14) , levels of stool DAF were elevated only in a small number of patients with these benign polyps. In that study, a single stool sample from each patient was examined. The testing of multiple samples may increase the sensitivity, but the stool DAF test may not be sensitive enough to detect small lesions of colorectal adenomatous polyps.
In colorectal cancer, admittedly, the sensitivity of the stool DAF test for relatively small tumors (Յ2 cm) is low (35%), and the sensitivity significantly increased according to the tumor size, as one would likely expect. However, the sensitivity did not change significantly according to TNM stage. Obviously, the TNM stage of cancer does not necessarily correlate with the tumor size. The amount of DAF released from colorectal cancer may likely correlate with the surface area of the tumor exposed to the colonic lumen rather than with the depth of tumor invasion. Importantly, the test was positive in a significant portion of patients with colorectal cancer who had relatively early lesions without metastasis (TNM stages 0, I, and II), which are at potentially curable stages. Thus, a positive stool DAF test, especially in patients whose FOB test is negative, may be of great importance.
We conclude on the basis of this and our previous studies that measurement of stool DAF is worthy of further con- 
